Indivior Pharmaceuticals (INDV) Operating Leases (2021 - 2025)
Historic Operating Leases for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $24.0 million.
- Indivior Pharmaceuticals' Operating Leases rose 16857.14% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 16857.14%. This contributed to the annual value of $32.0 million for FY2024, which is 588.24% down from last year.
- As of Q3 2025, Indivior Pharmaceuticals' Operating Leases stood at $24.0 million, which was up 16857.14% from $29.0 million recorded in Q2 2025.
- Indivior Pharmaceuticals' Operating Leases' 5-year high stood at $44.0 million during Q4 2021, with a 5-year trough of -$35.0 million in Q3 2024.
- Over the past 5 years, Indivior Pharmaceuticals' median Operating Leases value was $26.5 million (recorded in 2025), while the average stood at $5.6 million.
- In the last 5 years, Indivior Pharmaceuticals' Operating Leases tumbled by 1666.67% in 2024 and then surged by 19375.0% in 2025.
- Indivior Pharmaceuticals' Operating Leases (Quarter) stood at $44.0 million in 2021, then decreased by 15.91% to $37.0 million in 2022, then dropped by 8.11% to $34.0 million in 2023, then fell by 5.88% to $32.0 million in 2024, then decreased by 25.0% to $24.0 million in 2025.
- Its Operating Leases stands at $24.0 million for Q3 2025, versus $29.0 million for Q2 2025 and $30.0 million for Q1 2025.